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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is 
Aristada (aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult 
patients?” 
 
STUDY DESIGN: Review of three randomized controlled studies.  All three trials were 
conducted between 2014 and 2015. 
 
DATA SOURCES: One randomized, controlled trial and two randomized, controlled, double-
blind trials found via Cochrane Library and PubMed. 
 
OUTCOMES MEASURED: The outcomes that were measured include adverse events (pain at 
injection site, insomnia, headache, toothache, abdominal discomfort, constipation, diarrhea, 
akathisia, back pain, dyskinesia, dystonia, nasopharyngitis) measured by vital signs, physical 
examination, and clinical laboratory tests.  Improvement in psychotic symptoms measured by 
PANSS (Positive and Negative Syndrome Scale) and CGI-I scale (Clinical Global Impressions-
Improvement Scale).  Also, effect on agitation and hostility measured by PANSS, Personal and 
Social Performance Scale, and disturbing and aggressive behavior. 
 
RESULTS: The three randomized, controlled trials showed that the use of aripiprazole lauroxil 
was effective at reducing symptoms of schizophrenia including hostility and agitation, based on 
PANSS, CGI-I, and PSP scores.  Results in reducing symptoms were seen as early as 8 days after 
initial administration in some cases.  Aripiprazole lauroxil was also found for be safe in the trials 
with, only a limited number of mild to moderate adverse events occurring among certain 
participants in the studies, mostly injection site pain.  
 
CONCLUSIONS: Based on these three trials, Aristada (aripiprazole lauroxil) is a safe and 
effective treatment option for schizophrenia in adult patients. 
 
KEY WORDS: Aripiprazole lauroxil, schizophrenia 	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INTRODUCTION 
 Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, 
feels and behaves.4  Aripiprazole lauroxil is a new, novel LAI atypical antipsychotic that may be 
used for the treatment of schizophrenia.  This paper evaluates three randomized, controlled trials 
comparing the effectiveness and safety of Aristada (aripiprazole lauroxil) in treating the 
symptoms of schizophrenia in adult patients. 
 Schizophrenia is relevant to patients and Physician Assistant practice due to its 
prevalence, cost to patients, and the number of health care visits per year from it.  Schizophrenia 
affects 7.2 individuals per 1,000 living in the United States and about 100,000 people living in 
the country will be diagnosed this year.5  The overall United States health care cost of 
schizophrenia was estimated to be $62.7 billion in 2002, with $5 billion of that for drugs alone.5  
The 12 month health care use rate is 60% of adult patients with schizophrenia.4  Due to all of 
these reasons, it is imperative for Physician Assistants to be aware of schizophrenia and the 
burden that it places on patients who are affected by it. 
 The exact etiology of schizophrenia is unknown.  It is a complex condition that is 
increasingly being recognized as a collection of different disorders.  Genetic influence has been 
found to play a role.  It is also being viewed from a developmental perspective.4  Symptoms of 
schizophrenia are classified as “positive” or “negative”.  The positive symptoms include 
hallucinations, delusions, and thought disorders.4  The negative symptoms include lack of 
motivation to accomplish goals, blunted affect or emotion, and lack of desire to form social 
relationships.4  There is currently no curative treatment for schizophrenia, and its treatment is 
aimed at symptom control. 
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The typical first line treatment for schizophrenic patients is with atypical antipsychotics 
or the older “typical” antipsychotics.  Atypical antipsychotics include Risperidone, Quietiapine, 
Olanzapine, Clozapine, Asenapine, and Ziprasidone.  “Typical” antipsychotics include 
Chlorpromazine, Fluphenazine, Haloperidol, and Perphenazine.  Other treatment options include 
psychosocial support, cognitive behavioral therapy, rehabilitation, and family support.  Patients 
may choose to utilize a combination of treatment options that work most effectively for control 
of their symptoms.  Due to lack of efficacy and contraindications to other treatment options, 
Aristada (aripiprazole lauroxil) may be used as an effective treatment for schizophrenia in adult 
patients. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Is Aristada 
(aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult patients?” 
METHODS 
 The criteria used for selection of studies in this review included a population of adult 
patients between the ages of 18 and 70 who have been diagnosed with schizophrenia and are 
experiencing an acute exacerbation.  The intervention was the administration of aripiprazole 
lauroxil 441 mg IM or 882 mg IM.  Comparisons were made between the treatment groups 
receiving aripiprazole lauroxil to the experimental groups who received a placebo.  Outcomes 
measured included adverse events (pain at injection site, insomnia, headache, toothache, 
abdominal discomfort, constipation, diarrhea, akathisia, back pain, dyskinesia, dystonia, and 
nasopharyngitis), improvement in psychotic symptoms, and effect on agitation and hostility.  The 
studies included one randomized, controlled trial and two randomized, controlled, double-blind  
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trials that evaluated aripiprazole lauroxil as an effective treatment for schizophrenia in adult 
patients.   
 The key words used when searching for the articles included “schizophrenia” and 
“aripiprazole lauroxil”.  All of the chosen articles were published in English and in peer-
reviewed journals.  The articles chosen were researched by the author and selected after being 
searched via Cochrane Library and PubMed.  The articles were selected based on relevance to 
the clinical question, the types of studies, and whether or not the outcomes mattered to patients.  
The inclusion criteria included patients aged 18 and up diagnosed with schizophrenia by DSM-
IV-TR criteria, and studies that were randomized, controlled trials evaluating efficacy and safety 
of aripiprazole lauroxil.  The exclusion criteria included studies with patients under the age of 18 
years, and studies that did not provide information on efficacy of aripiprazole lauroxil in treating 
schizophrenia.  The statistics reported or used include p-values and percentages.  Table 1 
displays demographics and characteristics of included studies. 
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Table 1: Demographics & Characteristics of included studies: 
Study Type # 
Pts 
Age 
(yrs
) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Turncliff1 
(2014) 
RCT 46 18-
55 
yrs 
-Aged 18 to 55 
yrs with 
chronic 
schizophrenia 
or 
schizoaffective 
disorder 
-BMI of 18 to 
40 kg/m2 
-On stable 
med >2 
months 
-Previous 
aripiprazole 
use 
-Suicidal 
behavior/ideation 
-Any unstable 
medical illness 
-Use of 
aripiprazole within 
60 days of 
screening 
-Substance abuse 
within 3 months of 
screening 
-Women pregnant 
or breastfeeding 
-Corrected QT 
interval 
3 Aripiprazole 
lauroxil 441 
mg IM 
(Deltoid vs. 
Gluteal 
administration) 
Meltzer2 
(2015) 
Double 
blind 
RCT 
623 18-
70 
yrs 
-Aged 18-70 
with 
schizophrenia 
and 
experiencing 
an acute 
exacerbation 
-PANSS score 
of 70 to 120 
-Outpatient >3 
months 
-Significant 
medical illness 
-Women pregnant 
or breastfeeding 
-Substance 
dependence 
-Previous 
inadequate 
response to 
aripiprazole 
-Comorbid 
cognitive disorder  
262 Aripiprazole 
lauroxil 441 
mg & 882 mg 
gluteal IM 
Citrome3 
(2015) 
Double 
blind 
RCT 
622 18-
70 
yrs 
-Aged 18-70 
yrs with 
schizophrenia 
-Currently 
experiencing 
acute 
exacerbation 
-Outpatient for 
more than 3 
months 
-PANSS total 
score of 70 to 
120 
 
-Received long-
acting 
antipsychotics and 
agents that would 
effect metabolism 
of aripiprazole 
lauroxil 
- Currently 
hospitalized 
involuntarily 
-Use of MAO 
inhibitors, lithium, 
mood stabilizers 
27 Aripiprazole 
lauroxil 441 
mg & 882 mg 
IM 
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OUTCOMES MEASURED 
 The outcomes measured in the trials were all patient-oriented evidence that matters.  In 
Turncliff et al study, the outcomes measured were safety evaluations for adverse events and 
injection site reactions that were measured using clinical laboratory testing, physical 
examination, vital signs, and 12-lead electrocardiogram.1  Blood samples were collected at pre-
specified times to determine plasma concentrations of the drug in the patients after IM dosing.1  
The C-SSRS was used at screening, baseline, and during the trial to evaluate patients for suicidal 
ideation, and the ESRS was used to evaluate patients for extrapyramidal symptoms.1  In Meltzer 
et al study, the Positive and Negative Syndrome Scale (PANSS) and Clinical Global 
Impressions-Severity of Illness scale(CGI-S) were used, along with the Clinical Global 
Impressions-Improvement scale (CGI-I) to measure efficacy of aripiprazole lauroxil to improve 
psychotic symptoms.2  Safety was also evaluated in Meltzer et al study, through monitoring 
adverse events measured by vital signs, physical examination, ECG findings, injection site 
reaction evaluation, and lab tests.2  In Citrome et al study, the effect of aripiprazole lauroxil on 
agitation and hostility was measured using PANSS and the Personal and Social Performance 
(PSP) scale.3  The PANSS Hostility item P7 and the PANSS-EC (excited component) were 
components of PANSS used to determine the effects on agitation and hostility as well. 
RESULTS 
 The three randomized, controlled trials in this EBM review all demonstrated statistical 
results based on their respective studies. 
 In the Turncliff et al study, 38 (82.6%) of patients experienced at least one treatment-
emergent adverse event.  All of these adverse events were mild or moderate in intensity.1  The  
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incidence of adverse events was higher in the deltoid administration group.  The most common 
adverse event was injection site pain in 20 (43.5%) subjects.1  The most common systemic 
adverse events were headache (13.0%), insomnia (10.9%), and toothache (10.9%).1  The adverse 
events of dyskinesia and dystonia each occurred in 3 subjects (13.6%) in the deltoid group, but 
not the gluteal group.  No severe adverse events occurred during the study and no 
discontinuations due to adverse events occurred.1  No clinically significant effects of aripiprazole 
lauroxil on vital signs, physical examination, or 12-lead electrocardiogram were found.1  
Changes from clinical laboratory tests were small, with no patterns of change with time or 
differences between the treatment groups observed.1  There were no clinically significant 
changes from baseline for ESRS between treatment groups, and changes that occurred were 
small.1  No post-baseline responses were noted on the C-SSRS, with no suicidal behavior or 
attempts in any subjects.1  
 In the Meltzer et al study, a clinically meaningful change from baseline to day 85 in 
PANSS total score was demonstrated for the aripiprazole lauroxil 441 mg and 882 mg groups, 
with placebo-adjusted least squares mean differences of -10.9 (1.8) (P<.001) and -11.9 (1.8) 
(P<.001).2  These improvements for both of the treatment groups were observed as early as day 
8.  Both the 441 mg and 882 mg groups had significantly better CGI-I scores at day 85 compared 
to placebo (P<.001).2  A Wilcoxon rank sum test was used to determine this.  The number of 
patients who were much or very much improved was also significantly greater in both the 441 
mg and 882 mg groups compared to placebo at every assessment after day 8.  (P<.05 to P<.001).2  
The study also looked at adverse events in a similar fashion to the Turncliff et al study.  The 
adverse events that occurred were mostly mild or moderate in intensity.  The only serious   
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adverse event that was considered related to the study drug was akathisia in a patient in the 882 
mg group.2  More patients in the placebo group discontinued the study due to adverse events 
(17.9%) compared to the 441 mg group (6.8%) or the 882 mg group (2.9%), attributed to 
exacerbation of the underlying illness.2  Treatment-emergent adverse events occurred in ≥ 2% of 
patients in the treatment groups.  The most common of these were insomnia, akathisia, headache, 
and anxiety.2  Akathisia was the only treatment-emergent adverse event that occurred with an 
incidence ≥ 5% in each treatment group that was double the incidence in the placebo group.2  
Most (>75%) of the episodes of akathisia occurred before the second injection of aripiprazole 
lauroxil was administered.  The incidence of injection site reactions was low overall, with 8 
(3.9%), 12 (5.8%) and 4 (1.9%) patients for the 441 mg, 882 mg and placebo groups 
respectively.2  The most common injection site reaction was pain, with redness, swelling or 
induration rarely reported.2  Data on p-vales from the trial is included in Table 2. 
Table 2 
 441 mg Aripiprazole Lauroxil 882 mg Aripiprazole Lauroxil 
Placebo-adjusted least square 
mean difference improvement 
in PANSS baseline to day 85 
-10.9 (1.8) -11.9 (1.8) 
P value  P<.001 P<.001 
Placebo-adjusted mean change 
in PANSS day 85 
-14.7 (3.5) -16.6 (3.4) 
P value  P<.0001 P<.0001 
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Finally, in the Citrome et al study, the mean baseline PANSS total scores showed that 
patients in the study were severely impaired (score >90).3  The mean total PSP score at baseline 
was ≈	 50, indicating severe difficulties with social and personal functioning.3  The proportion of 
patients with a PANSS hostility item P7 more than 1 was significantly lower for each 
aripiprazole lauroxil group compared to placebo at the end of the study.3  At day 85, aripiprazole 
lauroxil 441 mg 53.6% (P=0.01), aripiprazole lauroxil 882 mg 46.1% (P<0.001) and placebo 
66.3%.3  Statistically significant changes were also observed at days 22, 29, and 57 of the study.3  
When measuring the PANSS excited component, a significant improvement (P<0.001) was 
observed with both aripiprazole lauroxil groups compared with placebo at days 8, 15, 22, 29, 57, 
and 85.3  The improvement was greater in the 882 mg group compared to the 441 mg group.  
Significant improvements were observed for both aripiprazole lauroxil groups versus placebo for 
the PSP disturbing and aggressive behavior domain at day 85.  These results were placebo 
44.1%, aripiprazole lauroxil 441 mg 30% (P=0.007 vs. placebo) and aripiprzole lauroxil 882 mg 
22.2% (P<0.001 vs. placebo).  
DISCUSSION 
 The three studies combined display evidence that Aristada can be used as both a safe and 
effective treatment of schizophrenia.  The Turncliff et al study demonstrated that IM 
administration of aripiprazole lauroxil is tolerable in adult patients with chronic stable 
schizophrenia.1  The higher incidence of injection site reactions in the deltoid administration 
group shows that gluteal injections may be the preferred method in the future for patients who 
have a lower tolerance for pain.  The most common injection site reaction being pain is not 
surprising as some small level of pain can be expected with IM injections.  Still, only 43.5% of  
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subjects experienced this adverse event.1  Patients who experience dyskinesia or dystonia may be 
better served receiving their injection via gluteal administration as well since no subjects in the 
gluteal group experienced those adverse events.1  The lack of clinically significant changes to 
vital signs, physical examination, and ECG demonstrate that while some mild adverse events 
may occur, overall it is safe to administer aripiprazole lauroxil IM.  A limitation to this study was 
the smaller amount of patients who participated in it. 
 The Meltzer et al study showed that clinically and statistically significant negative 
changes occurred to the PANSS scores, meaning that both treatment groups were effective at 
reducing the symptoms of schizophrenia.2  The drug may begin to work as early as 8 days after 
administration as evidenced by the study.2  The statistically significant, improved CGI-I scores at 
day 85 of the study also supports that Aristada can effectively treat schizophrenia.2  The greater 
improvement in the PANSS total score in the 882 mg group suggests that it may be more 
beneficial to administer a higher dose in patients with more severe symptoms.2  This randomized, 
double-blind, placebo controlled trial also showed that Aristada is a safe option for schizophrenic 
patients.  Both doses were well tolerated among patients with the incidence of treatment 
emergent adverse events remaining low and not appearing to be related to dose.  Akathisia 
occurred in patients in both groups and seemed to coincide with the first injection for the 
majority of episodes.  This is something that a follow-up study could more closely examine to 
further investigate the incidence of adverse events of aripiprazole lauroxil. 
 The Citrome et al study showed similar results to the two previously mentioned trials.  
The patients were found to have severe social and personal functioning based on PANSS scores 
at baseline, and these improved dramatically after the administration of aripiprazole lauroxil.3   
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The PANSS hostility item P7 improvements seen in patients, demonstrate that reductions in 
hostile behaviors occurred.3  The reductions in aggressiveness and hostility are important to note 
because these are symptoms commonly seen in schizophrenic patients.  This study provides more 
evidence that aripiprazole lauroxil can effectively reduce symptoms of schizophrenia in chronic 
schizophrenics who are severely affected by the disorder. 
CONCLUSION 
 Based on this systematic review and its included studies, Aristada (aripiprazole lauroxil) 
is an effective and safe treatment for schizophrenia in adult patients.  All three studies showed 
that the drug was well tolerated and was able to reduce symptoms of schizophrenia.  The risks of 
the mild to moderate adverse events experienced by patients in the trials do not outweigh the 
benefits of effectively reducing symptoms associated with schizophrenia including agitation and 
hostility.  Patients who wish to exhibit better control of their schizophrenic symptoms may find 
Aristada to be their treatment method of choice.  Aristada may still be combined with other 
forms of treatment such as psychosocial support and cognitive behavioral therapy to achieve the 
greatest individualized results for patients.  Future studies on Aristada could focus on more long-
term effectiveness of Aristada over the course of a year.  Future studies could also focus on how 
effective Aristada is when combined with other treatments for schizophrenia such as cognitive 
behavioral therapy.  There is still more research to be done about Aristada but the results of the 
studies included in this evaluation demonstrate that it is a drug worth keeping on the radar of 
Physician Assistants and other healthcare practitioners across the country.  It is with the 
knowledge of treatment options like Aristada that Schizophrenia can be effectively treated for 
symptomatic control and to reduce healthcare costs. 
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